FDA OKs Two Gene-Editing Therapies for Sickle Cell Disease

The FDA approved two gene-editing treatments for patients aged 12 years or older with severe sickle cell disease, marking the first cell-based gene therapies for the condition. Exa-cel uses CRISPR gene-editing technology and demonstrated success in a clinical trial, while Lovo-cel uses a different technology and also showed positive results. Both treatments were found to be largely effective and have potential side effects. Access to these treatments is seen as a potential concern due to high costs. The approval of these gene therapies represents a significant step for the sickle cell community despite potential issues related to accessibility.

Source link

21 thoughts on “FDA OKs Two Gene-Editing Therapies for Sickle Cell Disease

Leave a Reply

Your email address will not be published. Required fields are marked *